FDA will fill more than 1300 positions within the next several months.
Rockville, MD-April 30, 2008-Biologists, chemists, medical officers, mathematical statisticians and investigators are among the experts in demand as the U.S. Food and Drug Administration begins a multi-year hiring initiative.
The FDA is hiring hundreds of individuals with science and medical backgrounds to help meet the agency’s responsibilities to assure the safety and/or efficacy of human and veterinary drugs, biological products, medical devices, food, cosmetics, and products that emit radiation.
“It takes a large pool of talented people for the FDA to protect and promote the public health,” said John Dyer, FDA’s deputy commissioner for operations and chief operating officer. “Each month there is a delay in bringing critical staff on board impairs the agency’s ability to fulfill this mission.”
In fiscal year 2008 alone, the FDA is looking to fill more than 600 new positions and to backfill over 700 others to implement the FDA Amendments Act of 2007, the Food Protection Plan and the Import Safety Action Plan. That’s nearly triple the number of people hired from 2005–2007.
The Office of Personnel Management has granted Direct-Hire Authority to the FDA, an operating division of the Department of Health and Human Services. OPM’s actions reflect the Administration’s commitment to strengthening the agency quickly.
Direct-Hire Authority is an appointing authority OPM can give to federal agencies for filling vacancies when a critical hiring need or severe shortage of candidates exists. It expedites hiring of qualified candidates by eliminating certain rating and ranking preferences. Qualified candidates could be on the job in as little as three weeks.
The critical need occupations are medical officers, consumer safety officers, chemists, nurse consultants, biologists, microbiologists, health/regulatory/general health scientists, mathematical statisticians, epidemiologists, pharmacologists, pharmacists, and veterinary medical officers. Many of these positions are located in the Washington metropolitan area, specifically Rockville; Silver Spring; and College Park, MD, as well as across the country in the FDA’s five regions, 20 districts, more than 179 resident posts, and the newly created FDA offices overseas.
Positions will be available throughout the agency, including in the Center for Biologics Evaluation and Research, the Center for Drug Evaluation and Research, the Center for Devices and Radiological Health, the Center for Food Safety and Nutrition, the Center for Veterinary Medicine, the National Center for Toxicological Research, the Office of the Commissioner, and the Office of Regulatory Affairs.
The FDA will be participating in and holding job fairs throughout the country. To find a job fair near you, visit www.fda.gov/jobs. For general information and to apply for one of the positions listed above, submit your questions and electronic curriculum vitae with a cover letter via email at JOINOURTEAM@FDA.gov.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.